AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit
Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has...
October 2023
AffaMed Technologies Secures Exclusive Rights to SIFI’s Intraocular Lens Products in Greater China
AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced...
Simcere Pharmaceutical Secures Exclusive Rights to AnDiCon’s Anti-Influenza Candidate ADC189
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced a strategic collaboration agreement with domestic firm...
J&J’s Janssen Reports Favorable Spravato Data in Late-Stage TRD Trial
Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, has presented tolerability and efficacy data from...
BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology...
Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology
The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen...
Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million
Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on...
Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4
Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...
FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment
The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for...
Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery...
Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030
The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...
ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with...
Alphamab Oncology Enters Licensing Agreement with Grand Life Sciences for KN057 in Greater China
China-based Alphamab Oncology (HKG: 9966) has announced a licensing agreement with fellow Chinese firm Grand...
Chongqing Zhifei Partners with GSK for Shingrix Distribution in China
China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and...
Mabwell Bioscience Enters Licensing Agreement with Laboratorios Legrand for Biosimilars in Colombia and Ecuador
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a strategic licensing agreement with...
Innovent Biologics Doses First Patient in Phase 3 Study of IBI302 for Neovascular AMD
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient with neovascular age-related...
NHSA Issues Guidelines to Strengthen Medical Insurance Payment Management
The National Healthcare Security Administration (NHSA) has released a set of guiding opinions aimed at...
Sino Medical Sciences’ HT Supreme Stent System Included in French Reimbursement List
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in China,...
HutchMed and Takeda Submit Fruquintinib NDA for Metastatic CRC in Japan
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that its partner Takeda (TYO: 4502) has...
Bio-Thera Solutions’ BAT1806 Receives US FDA Approval as Biosimilar to Actemra/RoActemra
Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, announced that its biosimilar version of...